ABSTRACT: Nanoparticle-based magnetic resonance imaging T 2 negative agents are of great interest, and much effort is devoted to increasing cellloading capability while maintaining low cytotoxicity. Herein, two classes of mixed-ligand protected magnetic-responsive, bimetallic gold/iron nanoparticles (Au/Fe NPs) synthesized by a two-step method are presented. Their structure, surface composition, and magnetic properties are characterized. The two classes of sulfonated Au/Fe NPs, with an average diameter of 4 nm, have an average atomic ratio of Au to Fe equal to 7 or 8, which enables the Au/Fe NPs to be superparamagnetic with a blocking temperature of 56 K and 96 K. Furthermore, preliminary cellular studies reveal that both Au/Fe NPs show very limited toxicity. MRI phantom experiments show that r 2 /r 1 ratio of Au/Fe NPs is as high as 670, leading to a 66% reduction in T 2 relaxation time. These nanoparticles provide great versatility and potential for nanoparticle-based diagnostics and therapeutic applications and as imaging contrast agents.
■ INTRODUCTION
Magnetic resonance imaging (MRI) is a powerful diagnostic technique primarily used to visualize fine morphological features of the human body with spatial resolution down to the submillimeter range, yielding valuable information on function and metabolism. 1 However, a limitation of MRI is its lack of sensitivity to relaxation times between normal and abnormal soft tissue, resulting in low contrast images. With the introduction of contrast agents in MRI, more specific and clear images can be obtained, providing physicians with sensitive and substantial diagnostic information. 2 More recently, molecular and cellular MRI has been intensively studied to visualize and track target cells in living organisms, for example, to verify homing or engraftment of transplanted stem cells. 3 In order to provide a characteristic difference in MRI signal intensity, cells must be prelabeled with MRI contrast agents in vivo or in vitro. Nanostructured contrast agents based on both superparamagnetic iron oxides (SPIONs, T 2 negative agents) and paramagnetic chelates (Gd 3+ and Mn 2+ , T 1 positive agents) have been used for this purpose. 4 When prelabeling cells in vitro, the challenge is to induce sufficient cellular uptake of the contrast agent without affecting normal cellular functions. In addition, cells should retain the contrast agent for a time sufficient to provide useful information by MRI, which could range from few minutes or hours for imaging to weeks for cell tracking. The efficiency of nanoparticle uptake by cells is directly influenced by the properties of the particle surface. 5−7 Extensive research has focused on increasing cellular uptake by surface modification strategies, such as conjugation of cell-penetrating peptides, 8 combination with transfection agents, 9 and encapsulation with dendrimers. 10 However, challenges still remain in achieving biological functionality as well as low toxicity, water solubility, and stability in biological media. Many recent studies report on the synthesis and MRI potential of Au-coated iron oxide nanoparticles 11 and Au/Fe bimetallic and alloy nanoparticles.
12−16 Both solutions lead to superparamagnetic nanoparticles with contrast agent capability that in addition present an exposed, inert, noble metal surface. The presence of Au provides two main advantages: (i) a wellknown and versatile platform for surface functionalization, the gold−thiol chemistry, and (ii) gold adds plasmonic features to the superparamagnetic NPs that can be exploited for multimodal imaging, such as contrast for CT (computed tomography) and SERS (surface enhanced Raman spectroscopy) imaging in vivo, 13 and photothermal therapy. 17 Our primary motivation is to develop magnetic nanoparticles that can be used as nontoxic, cell-degradation resistant MRI contrast agents, e.g., for long-term follow-up studies of transplanted stem cells or for in vitro and in vivo studies to follow tumor growth of NP-loaded tumor cells. The magnetoresponsive Au/Fe NPs described in this work combine the capability of cell internalization shown by mixed-ligand gold nanoparticles 5, 18, 19 with magnetic features.
A number of different methods have been previously reported for the preparation of bimetallic Au/Fe alloy nanoparticles, 13−15,20−26 core−shell or dumbbell nanoparticles, 27, 28 with protocols including thermal decomposition, 15, 23 pulsed laser deposition, 29, 30 microemulsion techniques, 16, 31 thermal vaporization, 32, 33 laser-assisted synthesis in solution, 13, 20 and aqueous reduction by borohydride derivates.
14 Chemical reduction of metal ions by sodium borohydrides has previously been used to prepare nanocrystalline magnetic materials, nanoalloys, and amorphous metals. 34, 35 In this work, we report a new two-step synthesis to prepare magnetoresponsive gold/iron nanoparticles (Au/Fe NPs) with two mixed-ligand coatings, either mercaptopropionylsulfonic acid:-o c t a n e t h i o l ( M P S A : O T ) o r m e r c a p t o u n d e c y lsulfonate:octanethiol (MUS:OT). Structural characterization and elemental analysis demonstrate that the resulting bimetallic nanoparticles have an average diameter of 4 nm (MPSA:OT, 4.0 ± 1.3 nm; MUS:OT, 4.0 ± 1.0 nm) with an average atomic ratio of Au to Fe of 7 (MPSA:OT) and 8 (MUS:OT), which enables Au/Fe NPs to be superparamagnetic at room temperature, with a blocking temperature of 56 K (MPSA:OT) and 96 K (MUS:OT), depending on the coating. Their high r 2 / r 1 ratio demonstrates their capability to be used as MRI T 2 contrast agents. Furthermore, we confirm their ability to penetrate cells and to be accumulated without apparent toxicity and to be retained in cells after cellular division up to the fourth generation. This combination of properties demonstrates the applicability of these nanoparticles as ideal MRI contrast agents.
■ RESULTS AND DISCUSSION
Synthesis and Physicochemical Characterization of Au/Fe Nanoparticles. We present a two-step method, which employs mild condition and is very easy to scale up. The synthesis of gold/iron nanoparticles (Au/Fe NPs) is performed in two steps in order to overcome the difference in the redox potential of iron and gold, as in most reducing conditions gold is reduced before iron. Therefore, the iron salts are first reduced to Fe 2 O 3 by quickly adding a mixture of ferric (Fe 3+ ) and ferrous (Fe 2+ ) salts into an excess of NaBH 4 solution. The reaction is very fast (less than a minute) and allows for high yields of the precursor iron complex. In the second step, the Fe precursor is mixed with gold salts and capping ligands and reduced with NaHB 4 to produce ligand-shell stabilized Au/ Fe NPs, following a well-established gold nanoparticle synthesis procedure. 36 Our bimetallic Au/Fe-NPs are passivated by a mixed ligand monolayer composed either by MPSA:OT or by MUS:OT mixtures. MPSA and MUS are hydrophilic molecules that phase-separate into patches on the gold surface when forming mixed ligands monolayer with hydrophobic moieties like OT.
MPSA:OT Au/Fe NPs are a useful benchmark system to compare with published reports on Au/Fe alloy nanoparticles with pure MPSA coating.
14 Compared to those reports, our NPs are obtained with a method independent of thermal decomposition or the presence of an organic surfactant, which can be difficult to remove and may cause cellular toxicity. 37 Moreover, our Au/Fe NPs present a mixed ligand surface that has proven to be highly biocompatible in similarly prepared pure gold NPs. Indeed, our group previously investigated gold nanoparticles coated with an alternate arrangement of hydrophobic and longer hydrophilic sulfonated moieties (MUS), showing in both in vitro and theoretical models a high capability to penetrate into cells. 5, 18, 19 Transmission electron microscopy (TEM) images reveal that the average diameter of MPSA:OT Au/Fe NPs is 4.0 ± 1.3 nm (Figure 1a) . Similar results are obtained for MUS:OT Au/Fe NPs (Figure 1b) , with a similar size distribution centered at 4.0 ± 1.0 nm. In bright-field mode of TEM, pure gold phases normally appear much darker than pure iron phases because of much higher proton number in gold atoms. Therefore, both Fe/Au core/shell NPs and phase-separated Fe and Au NPs are showing different contrast between the two phases in TEM images. 38 For example, both large scale ( Figure 1a ) and highresolution (Figure 1a 14 These kinds of peculiar bimetallic NPs where Fe is homogeneously distributed in the fcc crystal of gold core allow for the design of small-size contrast agent NPs (compared to core−shell design) that maintain plasmonic and magnetic properties. 12, 13, 21, 38, 39 Highresolution TEM images also reveal that MPSA:OT Au/Fe NPs have multiple twinned boundaries of AuFe, single-crystal and other crystal structures, substantially in a similar fashion as for 4 nm pure Au NPs observed by others. 38 These results, in addition to X-ray powder diffraction (XRD), reveal that the nanoparticle core (in both MPSA:OT and MUS:OT Au/Fe NPs) presents iron oxides, as well as with a slight degree of alloying with gold, thus supporting the presence in the core of both iron and gold and the protective effect of the gold lattice on the iron component.
The iron precursor shows the presence of crystalline iron oxides (Supporting Information, Table S1a,b) of ∼2 nm in size. MPSA:OT and MUS:OT Au/Fe NP core lattice parameters (4.0698 and 4.0681 Å, respectively, as estimated via Scherrer's formula; see Supporting Information Table S1b) show some relaxation compared to the crystal lattice of pure gold (lattice constant reported in the literature: 4.0782(5) Å [14] [15] [16] 31, 40 ). This suggests a slight degree of alloying, similar to previous reports.
14 −16,31,40 The corresponding peaks of iron and gold, reported in Figure 1e and Figure 1f , are analyzed and are in good agreement with reported values. [14] [15] [16] 31, 40 The lattice parameters of bulk Au/Fe alloys have been characterized in a wide range of compositions, for example, 3.3% Fe (4.0690 Å) and 20% Fe (3.995 Å). 41 Application of Vegard's law in this range allows for an estimation of the iron composition from the lattice parameter, which results in 10.3% Fe for MPSA:OT Au/ Fe NPs and 12.3% Fe for MUS:OT Au/Fe NPs.
By X-ray photoelectron spectroscopy (XPS), the average atomic ratio of MPSA:OT Au/Fe NPs is found to be around 7 (14.3% Fe). The value is in agreement (within experimental error) with the data obtained from XRD analyses and from EDS (energy dispersive X-ray spectroscopy, as reported in Supporting Information Figure S2 ). In this ratio region, Fe atoms occupy face-centered cubic (fcc) sites of Au atoms. 42 Furthermore, the particle surface must be dominated by Au atoms to avoid Fe oxidation, which is similar to small sized iron−platinum (FePt) nanoparticles with Pt segregation on the surface. 38, 43 The presence of gold on the surface of Au/Fe NPs ensures that they have the same surface properties as pure gold NPs. It should be pointed out that the ratio of Fe to Au is not identical for each single NP, and we provide an average number for the nanoparticle population. Similar results are obtained for MUS:OT Au/Fe NPs where the average atomic ratio of Au/Fe is found to be around 8 (12.5% at. Fe), again in the range of fcc arrangement of Fe and Au atoms. 42 In both cases, XPS data show also the coexistence of S 5+ and S 2− oxidation states on the surface of NPs (Figure 1c Figure S3 ) support the finding of the coexistence of MPSA and OT on the surface of Au/Fe NPs. The ligand ratio for MUS:OT Au/Fe NPs is 1.84:1, as determined by NMR (Figure 1h ). The ξ-potential of Au/Fe NPs dispersed in water is measured to be −25 ± 1 mV for MPSA:OT NPs and −28 ± 4 mV for MUS:OT NPs; thus they are anionic and exhibit excellent colloidal stability. Furthermore, the Au/Fe NPs retain the localized surface plasmon resonance (LSPR) characteristic of pure Au NPs, as evidenced by a lack of attenuation or shift in the position of Au/Fe NPs' plasmon peak (Supporting Information Figure S1c ). This is in agreement with similar properties of low-iron content, chemically synthesized Au−Fe alloy NPs, 14 (Figure 2d ). As compared to iron and iron oxide nanoparticles of the same size, these Au/Fe NPs have similar blocking temperature but a smaller magnetization, which is mainly contributed by the small Fe portion and its wide distribution.
The potential for deployment of these NPs as effective contrast agents in MRI is assessed through phantom experiments and in vitro MRI. The specific relaxivity (r 2 ) and the ratio r 2 /r 1 are the figure-of-merit for T 2 -weighted contrast agents, such as iron oxide nanoparticles. The higher is the r 2 /r 1 ratio, the better is the contrast efficiency. To examine the contrast characteristics of Au/Fe NPs as a MRI contrast agent, we acquire the ) represents the relaxation rate (R 2 ) enhancements (relative to pure water) of the nanoparticle suspension as a function of the Fe ion concentration. Usually, r 1,2 is obtained from the plot using the equation R 1,2 = 1/T 1,2 = (1/T 1,2 ) 0 + r 1,2 C, where R 1,2 is the relaxation rate of the aqueous solution of nanoparticles, (T 1,2 ) 0 is the relaxation time in absence of nanoparticles, and C is the concentration (mM) of iron. 47 This equation allows for a univocal parameter r to be extracted and compared among samples. This equation is well applied to r 1 of MPSA:OT and both r 1 and r 2 of MUS:OT NPs. However, MPSA:OT Au/Fe NPs show a nonlinear behavior in the presented Fe concentration range. Our R 2 data for MPSA:OT Au/Fe NPs, indeed, span a larger range of Fe concentrations and follow below 0.4 mM Fe content a linear regime to reach saturation in the range 0.4−0.8 mM Fe. By analyzing data with a quadratic polynomial of the kind R 2 = R 0 + r 2a C + r b C 2 , where R 2b is the relaxation rate of the aqueous NP solution, R 0 = 1/(T 2 ) 0 is the inverse of the relaxation time in absence of nanoparticles, and C is the concentration (mM) of iron, we can explain both behaviors. The high slope in the linear regime (r 2a = 113.9 mM −1 s −1 ) is related to the positive contribution of C until a turning point, highlighted by the negative r 2b value (r 2b = −86.3 mM
), is reached at (r 2a /2) r 2b = 0.66 mM Fe. Then, the high NP concentration may favor different exchange rates of the protons that contribute to the MR signal so that at higher NPs concentration those protons may have unequal access to the paramagnetic centers.
The phantom experiments in Figure 3a and Figure 3c show that both nanoparticles induce a hypointense signal in a concentration-dependent manner on the T 2 -weighted images. R 2 relaxation time increased significantly from 0.49 μM to 8.2 μM (6.7 μM for the MUS:OT) Au/Fe NP concentrations. The contrast of Au/Fe NPs suspensions is shown in the phantom experiments where a strong reduction of the signal intensity in T 2 -weighted images is observed (Figure 3a, Figure 3c ). The absolute value of r 1 and r 2 of Au/Fe NPs is low because of the small Fe portion and wide distribution. However, the unique surface structure of Au/Fe NPs allows dramatic increase of the r 2 /r 1 ratio. This behavior can be explained by the interplay of two main effects. First, the segmented regions of hydrophilic −SO 3 − groups in the NP's biligand shell may be capable of trapping large amounts of "icelike" water, 48 resulting in a larger r 2 relaxivity. 49 Second, the hydrophobic pure Au layer surface of the NPs may efficiently block the external water molecules from interacting with the Fe magnetic core, inducing a large decrease in the spin−lattice r 1 relaxivity. 50 The r 2 /r 1 ratio value is as high as 670 (for MPSA MUS:OT NPs show a slightly higher toxicity at the highest tested concentration as compared to the MPSA:OT NPs; however viability is well above 60% even at high doses (3.28 and 4.92 μM). The highest concentration (4.92 μM), indeed, represents a high dose of nanomaterial, while at concentration reasonable for in vivo applications (such as the one used for the confocal and MRI images, 1.64 μM) viability is above 80% for all NPs. These data are confirmed by LDH (lactate dehydrogenase) leakage test (Supporting Information Figure  S7 ). Cells that lose the integrity of the plasma membrane due to perforation or necrosis release the cytosolic enzyme LDH in the medium or extracellular space. For NP concentration between 0.05 and 0.4 mg/mL (0.4−3.24 μM), we can see that LDH release at 4 h is equal to or lower than that of the control at all concentrations. At 24 h, LDH release at the maximum concentration is about 3 times higher than control. After 48 h of NPs incubation, LDH release reaches a plateau at 0.1 mg/ mL and above (0.82 μM) with an LDH release that is about 2.5 times higher than control. These results are promising, as a high cell loading with NPs can be achieved with shorter incubation time (up to 24 h) while keeping cytotoxicity low.
We also observed that the more hydrophobic MPSA:OT NPs tend to aggregate with time at very high concentrations. Possibly, this higher tendency of MPSA:OT NPs to form larger cluster in medium over time reduces the uptake of smaller particles, masking toxicity at higher doses, compared to MUS:OT NPs.
One limitation of FACS analysis is that it does not discriminate between cellular internalization and adsorption to the cell surface. For this reason, complementary CLSM imaging studies are carried out to confirm that the nanoparticles are present into the cytosol. HeLa cells are incubated with either type of NPs for 4 h at 37°C. The overlay of the bright-field and fluorescence images clearly shows that HeLa cells internalize BODIPY-labeled Au/Fe NPs. We can exclude that free BODIPY is responsible for the signal, as we ensured the absence of unbound dye by a test developed by our laboratory 51 (data not shown). The diffuse high fluorescence intensity signal in the cytosol, for both MPSA:OT and MUS:OT NPs (see Figure 4b, Figure 4d ), indicates the homogeneous distribution of NPs in contrast to a spotty appearance typical of when NPs enter solely via endocytosis. This can be attributed to NP uptake both by endocytosis and by passive membrane diffusion. By preferring NP entry passively into the cytosol of the cells over classic active endocytic mechanisms, the NPs can be protected from (i) degradation in the metal-dissolving acidic conditions along the endocytic/lysosomal pathways 52 and (ii) expulsion from the cells. Hence, passive uptake is beneficial for long-term follow-up in applications such as stem cell loading for post-transplant tracking. Detailed studies on the mechanisms of entry and uptake are ongoing and will be the subject of a future paper.
MRI Imaging of Au/Fe NPs-Loaded Cells. To assess the imaging potential of the NPs, MR imaging of cells labeled with NPs are performed to quantify the T 2 relaxation time. MRI T 2 -weighted images of the cells labeled with nanoparticles showed an evident hypointensity (Figure 5a ) corresponding to a reduction in T 2 relaxation time when compared to the control cells. Magnetic iron-containing nanoparticles such as our Au/Fe NPs create a local perturbing field that leads to a marked shortening on proton relaxation time (T 2 relaxation time) in MRI process giving a negative signal. 47 ,53 
Bioconjugate Chemistry
Article Figure 5a shows a reduction in T 2 relaxation time as the NP concentration increases after 8 h of incubation. A total reduction of 66% in T 2 relaxation time is achieved for the highest concentration when compared to the control cells.
Monitoring Au/Fe NPs Concentration in Dividing Cells. In perspective of the potential future use as long-term or even permanent cell stain, the dependence of NP detection limit in cell generations is an important parameter. We therefore followed the NPs signal in subsequent cell divisions. For both fluorescence and MRI experiments, the number of cells analyzed is kept constant at each generation step, so to follow the dilution of the BODIPY-MPSA:OT Au/Fe NPs. We expect that upon cell division, the internalized NPs are divided between the mother and the daughter cells, diluting the fluorescence and MR signals.
CLS micrographs (Figure 5b) show that the HeLa cells retain a significant amount of BODIPY-MPSA:OT Au/Fe NPs after several generations. These NPs are detected after cell division up to the fourth generation. It is noteworthy that these NPs do not affect cell division or metabolism, while the growth rate is reportedly reduced by other magnetic nanoparticles agents. 5, 18, 19, 54 More importantly, these results are confirmed by MRI. Indeed we were able to detect the NPs in daughter cells, in similarly prepared samples (Figure 5c ). Although fluorescence is clearly more sensitive to diluted concentrations, our Au/Fe NPs, compared to untreated cells, continue to show a good contrast in MRI even upon dilution in subsequent generations. This fact, together with the findings about the low toxicity and limited interference with cell viability, supports the use of these nanoparticles for MRI visualization in vivo. We are indeed already investigating their usefulness for research on metabolic activity and differentiation of the transplanted stem cells and for studies of tumor progression in 3D cell culture of NP-loaded tumoral cells (manuscripts in preparation).
■ CONCLUSIONS
We have described a simple and novel way for synthesizing stable magnetically responsive bimetallic gold/iron nanoparticles and have demonstrated their high potential as MR imaging contrast agents with high r 2 /r 1 ratio. The presence of gold as a passivating layer prevents the oxidation of iron, thereby increasing the stability of the magnetic nanoparticles, and furthermore offers access to the versatile functionalization scheme of thiols on gold. The labeling of the Au/Fe NPs with a biocompatible monolayer and their retention in the cytosol pave the way for numerous biomedical applications, such as stem cell tracking by MRI and follow-up of cell therapy. A significant advantage of this synthesis is that it can be used as basis to design other nanoparticles by changing certain parameters. Nanoparticle diameter and magnetic properties can be tuned by changing the gold to iron ratio, and surface ligands can be exchanged or conjugated with biomolecules (e.g., antibodies, peptides, or proteins) to achieve target-directed MRI or imaging multimodality. Thus, these nanoparticles and their synthesis offer great versatility and potential for nanoparticle-based diagnostics, therapeutic applications, and imaging contrast agents.
■ EXPERIMENTAL PROCEDURES
Synthesis of Gold/Iron Nanoparticles (Au/Fe NPs). A summary of the nanoparticles used in this study is presented in Table 1 . Magneto-responsive Au/Fe NPs were prepared as follows. First, iron complexes are synthesized by chemical reduction before subsequent mixing with gold salts for preparation of Au/Fe NPs. For the preparation of iron complexes, a mixture of ferrous and ferric ions (FeCl 3 ·6H 2 O (1.24 g) and FeCl 2 ·4H 2 O (0.64 g) in 4 mL of acidic water) is 
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Article added very quickly, and with vigorous stirring, to a sodium borohydride (NaBH 4 ) solution in large stoichiometric excess (1 g in 150 mL of ethanol). The reaction is carried out under nitrogen atmosphere at room temperature. The reaction solution becomes black, resulting in a fine black precipitate that is further filtered and washed with ethanol. The final Au/ Fe NPs are prepared by adapting an existing procedure. 5 The prepared iron complex (100 mg) is added to NaBH 4 solution (1 g in 150 mL of ethanol) and sonicated for 1 h. The resulting dispersion is added dropwise (over a period of 1 h) to 0.9 mmol of gold salt (HAuCl 4 ) in 200 mL of ethanol and 0.9 mmol of thiolated ligands. The ligand solution consists of a mixture in 2:1 molar ratio of sulfonated to hydrophobic thiol, either MPSA:OT 2:1 or MUS:OT 2:1. The reaction is carried out under N 2 atmosphere and stirred for 3 h. The resulting particles are stored overnight at 4°C, then collected by filtration, washed 3 times (by ethanol, methanol, and acetone), and finally dried under vacuum. The dried black powder can be attracted by a magnet and redispersed into water (Supporting Information Figure S1a,b) for subsequent experiments.
Fluorescent Labeling of Nanoparticles. For the cell experiments, nanoparticles are labeled with BODIPY 650/665 nm (hereafter referred to as BODIPY) (Invitrogen, OR, USA) according to the protocol described by Verma et al. 5 The complete removal of free BODIPY after washing the labeled nanoparticle preparation is assessed according to the protocol in Andreozzi et al. 51 Nanoparticle Characterization. The absorption spectra of NP suspensions are recorded on a UV−vis spectrophotometer (Ultrospec 2100pro, Amersham Bioscience). NP surface charge is approximated by measuring the ζ potential using a Zetasizer Nano ZS (Malvern Instruments, Malvern, U.K.). The results are expressed as ζ potential (mV) ± 1 standard deviation (SD). NP size is measured by transmission electron microscopy (TEM). TEM analysis is performed with a Philips/FEI CM300 transmission electron microscope at 300 kV with an energy dispersive X-ray spectrometer (EDS) attached. X-ray photoelectron spectroscopy (XPS) spectra are acquired by using Kratos AXIS Ultra. Fourier transform infrared spectroscopy (FTIR) spectra are measured on a JACSO FT/IR6320. Magnetic properties are characterized by using a superconducting quantum interference device (SQUID) magnetometer (Cryogenic).
1 H NMR measurements of ligand composites on the surface of NPs are carried out on a Bruker Avance 300 spectrometer operating at a frequency of 400 MHz after washing and etching. Generally, 30 mg of NPs and 25 mg of potassium cyanide (KCN) are dissolved in 1 mL of methanol. The solution is sonicated for 4 h and then left stirring overnight. Afterward the solution is filtered through a 0.2 μm membrane filter to remove any gold, iron, and other insoluble components and subsequently analyzed.
XRD (X-ray Diffraction). The samples are front-loaded as is into the well of a sample-holder from PANalytical (The Netherlands) hewn out of a silicon single crystal. Then powder diagrams are recorded on an MPD PRO system (PANalytical, The Netherlands) using an automatic divergence slit; at the end the diagrams are converted to a fixed DS of 6 nonlabeled or magnetically labeled cells are collected, centrifuged, and resuspended in 0.3 mL of 2% agar at approximately 60°C and then chilled at 4°C to allow the suspensions to solidify for MRI. All experiments were performed in triplicates. MR images are acquired on a BioSpec 70/30 USR (Bruker, Ettlingen, Germany) preclinical MRI scanner. The system has a magnetic field strength of 7 T and a 30 cm warm bore diameter. The scanner is equipped with an actively shielded gradient system with integrated shims set up to second order. The maximum gradient amplitude is 400 mT/ m. MRI studies are carried out using a transceiver linear birdcage rf coil having a diameter of 72 mm. Preliminary 3-orthogonal plane gradient echo tripilot scan is used as a geometric reference for slice selection. T 2 -weighted images are acquired using a rapid acquisition with relaxation enhancement (RARE) sequence with the following parameters: FOV 8 × 8 cm 
